Eli Lilly has confirmed it will continue pursuing a biologics license application for retatrutide, its triple-hormone injection that produced weight loss exceeding 20 percent at 80 weeks in late-stage trials, despite an FDA determination that the compound is neither a protein nor a biological product.
The dispute centers on how the molecule is chemically classified. A federal court partially vacated the FDA’s non-biologic ruling in September 2025 and remanded the matter for further review. Lilly has since appealed to the U.S. Court of Appeals for the 7th Circuit. The litigation, which began in September 2024, remains unresolved.
The outcome could significantly affect how long Lilly retains market exclusivity for retatrutide in the United States — and when competitors may legally enter.
What happened
The FDA determined that retatrutide does not qualify as a biological product under the agency’s classification framework, concluding that the molecule is not a protein. That designation matters because it determines whether the drug is approved through a biologics license application (BLA) or a standard new drug application (NDA).
Lilly challenged the FDA’s determination in federal court. In September 2025, the court partially vacated the FDA’s ruling and remanded it for further review. Lilly has since appealed to the U.S. Court of Appeals for the 7th Circuit, where the classification question now awaits resolution.
Separately, the FDA has stated that retatrutide cannot be used in compounding under federal law. The agency cited the absence of an approved version of the drug, the lack of a United States Pharmacopeia (USP) monograph, and the compound’s placement on neither the 503A nor 503B bulk substances lists.
Why it matters
If the FDA’s non-biologic classification ultimately stands, retatrutide would be approved through a standard NDA, carrying five years of regulatory exclusivity. A biologics license, by contrast, carries 12 years of exclusivity — a seven-year difference that directly shapes when competitors can legally enter the U.S. market.
For biosimilar developers and potential competitors, the classification outcome will set the timeline for when alternative versions of retatrutide could become available. A BLA pathway would provide Lilly a longer competitive runway; an NDA pathway would shorten it considerably.
The compounding lockout remains in effect regardless of how the litigation is resolved. With no approved product, no USP monograph, and no listing on either the 503A or 503B bulk substances lists, there is currently no legal pathway for compounding pharmacies or telehealth providers to offer retatrutide to patients.
That means patients awaiting access to retatrutide — including those seeking it off-label — have no legal route to the drug until an approved version reaches the market.
What to watch next
- The 7th Circuit’s ruling on Lilly’s appeal, which could either uphold, reverse, or further complicate the FDA’s classification determination.
- Any FDA response to the court’s remand, should the appellate court return the matter to the agency.
- Lilly’s continued progress toward filing a biologics license application for retatrutide, regardless of the ongoing classification dispute.
- Any future FDA action on compounding eligibility for retatrutide, though the current barriers remain firmly in place.
Sources
Industry information only. Not medical or legal advice.
